Logo Logo Logo Logo Logo
  • VUR Review
    • Children & VUR
    • Diagnosing & Grading VUR
    • Prevalence & Resolution
    • VUR & UTIs
  • Treating VUR
    • VUR & Antibiotics
    • VUR & Open Surgery
    • VUR & Deflux
    • Looking at Treatment Options
  • About Deflux
    • How Deflux Works
    • Efficacy/Long-term Results
    • Treating with Deflux
    • Administering Deflux
    • Safety
  • For Urologists
    • Talking With Parents About VUR
    • Reimbursement
    • Product Insert
 

Find out about reimbursement

For information on Deflux reimbursement, please download the Deflux Reimbursement Guide here.

  • For Urologists
  • Talking With Parents About VUR
  • Reimbursement
  • Product Insert

  • VUR Review
    • Children & VUR
    • Diagnosing & Grading VUR
    • Prevalence & Resolution
    • VUR & UTIs
  • Treating VUR
    • VUR & Antibiotics
    • VUR & Open Surgery
    • VUR & Deflux
    • Looking at Treatment Options
  • About Deflux
    • How Deflux Works
    • Efficacy/Long-term Results
    • Treating with Deflux
    • Administering Deflux
    • Safety
  • For Urologists
    • Talking With Parents About VUR
    • Reimbursement
    • Product Insert
Deflux
  • Caregivers
  • Privacy Policy
  • Terms Of Use

©2019 Palette Life Sciences. All rights reserved.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Deflux is a registered trademark of Nestlé Skin Health S.A. used under license.

Deflux® (hyaluronic acid/dextranomer) is contraindicated in patients with any of the following conditions: non-functional kidney(s), hutch diverticulum, ureterocele, active voiding dysfunction, and ongoing urinary tract infection.

Safety and efficacy of treatment of duplex systems, use of more than 6 mL of Deflux (3 mL at each ureteral orifice) at the same treatment session, and treatment of children under 1 year of age have not been established.

APM039A